FULC Q4 2020 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FULCFulcrum Therapeutics, Inc.

$436M

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M

Gross Profit

-$12M-282.1% margin

Operating Income

-$18M-421.0% margin

Net Income

-$18M-419.4% margin

EPS (Diluted)

$-0.64

QoQ Revenue Growth

+128.6%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$130M

Total Liabilities

$34M

Stockholders' Equity

$95M

Cash & Equivalents

$57M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$0	—
Gross Profit	-$12M	-$519,000	-2196.7%
Operating Income	-$18M	-$16M	-7.9%
Net Income	-$18M	-$16M	-9.9%